Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Here’s How to Invest in the Cryptocurrency Trading Services Boom

By Chris Lau, InvestorPlace Contributor

Bitcoin and Cryptocurrency is surging once again, just as everyone else ignored it, but there's more than one way to get in on it.

Buy Sprint Stock Ahead of the T-Mobile Merger Approval

By Chris Lau, InvestorPlace Contributor

Sprint stock dipped slightly in recent sessions despite a good quarterly earnings report. Consider buying the dip before the merger.

JD.com Stock Can Rally After JD’s Q1 Results

By Chris Lau, InvestorPlace Contributor

JD.com could report ongoing positive revenue momentum on May 10, meaningfully boosting JD stock above its current level.

There’s an Outside Chance That Fitbit Stock Is Worth Another Look

By Chris Lau, InvestorPlace Contributor

Fitbit shares fell for months, ahead of the first-quarter earnings report. It fell even more after that. Where's the bottom for Fitbit stock?

Etsy Stock Likely to Get Boost From Better Than Expected Results Over the Long-Term

By Chris Lau, InvestorPlace Contributor

Etsy stock is on pause after a massive run-up. Expect strong growth in the upcoming Q1 earnings report to boost ETSY.

Stuck Allergan Stock Needs Blowout Q1 News In Next Week’s Earnings Report

By Chris Lau, InvestorPlace Contributor

Allergen needs to win back investors as the company continues to look for new drug products. AGN stock is stuck in a narrow trading range.

What to Do After Momo Stock Suffered a Serious Setback

By Chris Lau, InvestorPlace Contributor

The removal of Tantan, on instructions from the Chinese government, is a big setback for Momo stock. What should investors do next?

5 Biotech Stocks for a Long-Lived Portfolio

By Chris Lau, InvestorPlace Contributor

Biotech stocks fell sharply in the last few weeks, mostly on no new news. This drop may have created an entry point for investors.

Investors Should Take Another Look at IQ Stock Before Q1 Earnings

By Chris Lau, InvestorPlace Contributor

When iQIYI, Inc. (NASDAQ: IQ) began 2019 trading at around $15, the stock faced one big macro headwind related to the U.S.-China trade wars. Fast…

ATVI Earnings Probably Won’t Impress, But Expect Improvements Longer Term

By Chris Lau, InvestorPlace Contributor

Activision is not expected to impress investors when it reports first-quarter results. Beyond that, what are its prospects like?

Load More